| 7/12/2024 | IGLM | Takeda Pharmaceutical prices tender offer for 2026 notes
|
| 7/11/2024 | IGLM | Takeda Pharmaceutical tender offers oversubscribed at early deadline
|
| 6/28/2024 | IGLM | Takeda Pharmaceutical ups cap in tender offers to $1.5 billion
|
| 6/28/2024 | IG | New Issue: Takeda Pharmaceutical details $3 billion of notes in four parts
|
| 6/28/2024 | BKIG | S&P assigns BBB+ to Takeda notes
|
| 6/27/2024 | IG | New Issue: Takeda Pharmaceutical prices $3 billion of notes in four parts
|
| 6/27/2024 | IGLM | Takeda Pharmaceutical starts tender offers for up to $1 billion notes
|
| 6/26/2023 | IG | Moody’s raises Takeda ratings
|
| 9/28/2022 | IGLM | Takeda Pharmaceutical calls $1 billion of 4.4% senior notes due 2023
|
| 10/8/2021 | BK | Takeda to repay $1.7 billion term loan due 2025
|
| 9/27/2021 | IG | Moody's alters Takeda view to positive
|
| 7/12/2021 | EULM | Takeda Pharmaceutical calls 1.125% senior notes due 2022 at par
|
| 6/1/2021 | IG | S&P turns Takeda view to stable
|
| 4/19/2021 | IGLM | Takeda Pharmaceutical to redeem early remaining 2.45% notes due 2022
|
| 2/26/2021 | IGLM | Takeda Pharmaceutical redeems $300 million of 2.45% senior notes due 2022
|
| 9/2/2020 | SP | New Issue: Goldman prices $1.2 million leveraged basket-linked notes on 20 stocks
|
| 7/2/2020 | EMHYPFPV | Market Commentary: Steady post-holiday high-grade supply eyed; Takeda, Mondelez firm
|
| 7/2/2020 | IG | Market Commentary: Steady post-holiday high-grade supply eyed; corporate inflows climb; Takeda, Mondelez firm
|
| 7/2/2020 | IG | Market Commentary: Morning Commentary: High-grade issuers quiet ahead of holiday; inflows remain strong
|
| 7/1/2020 | EMHYPFPV | Market Commentary: Pre-holiday investment-grade supply quiets; Takeda notes mostly better
|
| 7/1/2020 | IG | Market Commentary: Pre-holiday investment-grade supply quiets; credit spreads firm; Takeda notes mostly better
|
| 7/1/2020 | IG | Market Commentary: Morning Commentary: High-grade supply quiets; Jabil holds fixed income investor calls
|
| 6/30/2020 | EMHYPFPV | Market Commentary: Mondelez, Societe Generale, Guardian Life, EBRD in primary
|
| 6/30/2020 | IG | Market Commentary: Mondelez, Societe Generale, Guardian Life, EBRD in primary; June deal supply heavy
|
| 6/30/2020 | IG | Market Commentary: Morning Commentary: Societe Generale, Mondelez, Guardian Life, EBRD plan primary tap
|
| 6/30/2020 | IG | New Issue: Takeda Pharmaceutical details $7 billion of notes in four parts
|
| 6/29/2020 | EMHYPFPV | Market Commentary: Takeda, Sumitomo Mitsui, MetLife Global, Equitable Financial, AEP, AIG price; EBRD on deck
|
| 6/29/2020 | IG | Market Commentary: Takeda, Sumitomo Mitsui, MetLife Global, Equitable Financial, AEP, AIG price; EBRD on deck
|
| 6/29/2020 | IG | New Issue: Takeda Pharmaceutical prices $7 billion of senior notes in four parts
|
| 6/29/2020 | IG | Market Commentary: Morning Commentary: Takeda, Sumitomo Mitsui, AEP, Equitable Financial offer notes
|
| 6/26/2020 | EMHYPFPV | Market Commentary: Lighter pre-holiday high-grade supply eyed; Takeda markets deal
|
| 6/26/2020 | IG | Market Commentary: Lighter pre-holiday high-grade supply eyed; Takeda markets deal; flows rebound; bonds mixed
|
| 6/26/2020 | IG | Market Commentary: Morning Commentary: High-grade supply quiets; Takeda continues marketing; flows rebound
|
| 6/25/2020 | EMHYPFPV | Market Commentary: Intuit prices $2 billion notes; United upsizes; Takeda markets deal
|
| 6/25/2020 | IG | Market Commentary: Intuit prices $2 billion notes; United upsizes; Takeda markets deal; inflows nearly double
|
| 6/25/2020 | BKIG | S&P rates Takeda notes BBB+
|
| 6/25/2020 | IG | Market Commentary: Morning Commentary: Intuit offers four tranches; United on deck; Takeda markets deal
|
| 6/25/2020 | BKIG | Moody’s assigns Takeda notes Baa2
|
| 6/25/2020 | IG | Takeda to price dollar-denominated fixed-rate notes in four tranches
|
| 4/24/2020 | SP | New Issue: Goldman prices $1.73 million leveraged basket-linked notes on 19 stocks
|
| 3/2/2020 | IGLM | Takeda Pharmaceutical to reduce debt via $1.03 billion divestments
|
| 12/18/2019 | IG | New Issue: Takeda sells $4.46 billion notes due 2021, 2023, 2028
|
| 8/29/2019 | IGLM | Takeda Pharmaceutical redeems in full its 3.8% senior notes due 2020
|
| 1/8/2019 | IG | S&P lowers Takeda
|
| 12/17/2018 | IG | Moody's downgrades Takeda
|
| 11/21/2018 | EMHYPFPV | Market Commentary: Kommuninvest upsizes; light supply forecast; Takeda mixed; GATX firms; Comcast eases
|
| 11/21/2018 | IG | Market Commentary: Kommuninvest upsizes; light supply forecast; Takeda mixed; GATX firms; Comcast eases
|
| 11/21/2018 | IG | Market Commentary: Morning Commentary: Kommuninvest tightens spread on three-year issue; Comcast recovers
|
| 11/20/2018 | IG | Market Commentary: HSBC Bank Canada prices; Kommuninvest eyes deal; Barclays, Marriott ease; Kroger mixed
|
| 11/20/2018 | IG | Market Commentary: Morning Commentary: High-grade primary quiet after Takeda deal; no reported bonds on tap
|
| 11/20/2018 | IG | New Issue: Takeda Pharmaceutical details $5.5 billion of notes in four tranches
|
| 11/19/2018 | EMHYPFPV | Market Commentary: Takeda sells $5.5 billion; Wisconsin Public Service, GATX price; PG&E, DowDuPont stable
|
| 11/19/2018 | IG | Market Commentary: Takeda sells $5.5 billion; Wisconsin Public Service, GATX price; PG&E, DowDuPont stable
|
| 11/19/2018 | IG | New Issue: Takeda Pharmaceutical prices $5.5 billion of senior notes in four tranches
|
| 11/19/2018 | IG | Market Commentary: Morning Commentary: GATX, Wisconsin Public Service offer notes; Takeda remains on deck
|
| 11/16/2018 | EMHYPFPV | Market Commentary: Takeda offers dollar notes; thin supply forecast; bonds widen; PG&E declines
|
| 11/16/2018 | IG | Market Commentary: Takeda offers dollar notes; thin supply forecast; bonds widen; PG&E, Volkswagen decline
|
| 11/16/2018 | IG | Takeda expected to price about $5 billion of notes in Nov. 19 week
|
| 11/16/2018 | IG | Moody’s gives Takeda notes A2
|
| 11/16/2018 | IG | Market Commentary: Morning Commentary: Takeda offers dollar notes following euro deal; bond flows negative
|
| 11/16/2018 | IG | Takeda plans seven-part dollar notes, sells €7.5 billion euro notes
|
| 11/16/2018 | IG | S&P rates Takeda's dollar notes A-, may downgrade to BBB+
|
| 11/14/2018 | EMHYPFPV | Market Commentary: DowDuPont prices $12.7 billion; Kilroy, World Bank sell green notes; bank paper widens
|
| 11/14/2018 | IG | Market Commentary: DowDuPont prices $12.7 billion; Kilroy, World Bank sell green notes; bank paper widens
|
| 11/14/2018 | IG | Market Commentary: Morning Commentary: Kilroy offers notes; DowDuPont, Takeda on tap; Handelsbanken firms
|
| 11/13/2018 | EMHYPFPV | Market Commentary: Handelsbanken, Marriott, U.S. Bancorp, Boston Properties price; DowDuPont, Takeda eyed
|
| 11/13/2018 | IG | Market Commentary: Handelsbanken, Marriott, U.S. Bancorp, Boston Properties price; DowDuPont, Takeda eyed
|
| 11/13/2018 | IG | Market Commentary: Morning Commentary: DowDuPont, Marriott, Boston Properties on deck; Takeda deal eyed
|
| 11/13/2018 | IG | Takeda Pharmaceutical holds roadshow for $14 billion of euro and possible dollar notes
|
| 11/9/2018 | IG | Moody’s rates Takeda notes A2
|
| 11/9/2018 | IG | S&P downgrades Takeda, rates euro notes A-
|
| 11/8/2018 | EMHYPFPV | Market Commentary: ING Groep prices $1.25 billion; volume light; Takeda eyes dollar-denominated deal
|
| 11/8/2018 | IG | Market Commentary: ING Groep prices $1.25 billion; volume light; Takeda considers dollar-denominated deal
|
| 11/8/2018 | IG | Takeda Pharmaceutical to hold roadshow for euro notes and potential dollar-denominated deal
|
| 5/9/2018 | IG | Moody's lowers Takeda Pharmaceutical
|
| 5/9/2018 | BKIG | S&P reviews Shire, Takeda
|
| 7/13/2017 | IG | S&P gives A- to Takeda bonds
|
| 7/13/2017 | IG | Moody's rates Takeda notes A1
|
| 7/11/2017 | EMHYPFPV | Market Commentary: Scotiabank, ANZ, Municipality Finance price; deal calendar takes shape; Whole Foods firms
|
| 7/11/2017 | IG | Market Commentary: Scotiabank, ANZ, Municipality Finance price; deal calendar takes shape; Whole Foods firms
|
| 7/11/2017 | IG | New Issue: Takeda Pharmaceutical sells $500 million 2.45% notes due 2022 at 55 bps over Treasuries
|
| 2/27/2017 | IG | S&P downgrades Takeda
|
| 1/11/2017 | IG | S&P puts Takeda on watch
|
| 1/10/2017 | IG | Moody’s may downgrade Takeda
|
| 2/29/2016 | SP | Market Commentary: HSBC prices $3.01 million of jump securities linked to WisdomTree Japan Hedged Equity fund
|
| 12/3/2014 | IG | Moody’s cuts five Japanese corporates to A1
|
| 10/21/2014 | IG | S&P downgrades Takeda to A+/A-1
|
| 7/10/2012 | IG | S&P rates Takeda bonds AA-
|
| 7/10/2012 | IG | Moody's rates Takeda notes Aa3
|
| 7/10/2012 | IG | Market Commentary: Pipeline open with Westpac, Sumitomo, ING, Penske in market; new issues tighten in secondary
|
| 7/9/2012 | IG | New Issue: Takeda Pharmaceutical prices $3 billion of bonds in three-, five-year tranches
|
| 7/9/2012 | IG | Market Commentary: Primary comes back to life as Monsanto, Cabot, Mitsubishi, Takeda price; bank, broker wider
|
| 3/13/2012 | IG | Moody's: Takeda bonds Aa3
|
| 6/24/2009 | SS | Takeda completes $2.64-per-share tender offer to acquire IDM Pharma
|
| 6/23/2009 | SS | Takeda to complete acquisition of IDM Pharma via short-form merger
|
| 5/26/2009 | SS | Takeda subsidiary begins $2.64-per-share tender offer for IDM Pharma
|
| 5/18/2009 | SS | Takeda to buy IDM Pharma for $2.64 per share; deal to close in June
|
| 8/4/2008 | SS | Market Commentary: ImClone rejects $60 per share offer; Blackstone shops for theme parks; PeopleSupport jumps on Aegis buy
|
| 5/14/2008 | SS | Takeda completes subsequent offer for Millennium; merger set to close Wednesday
|
| 5/9/2008 | SS | Takeda completes tender offer for Millennium Pharmaceuticals; subsequent offer to end May 13
|
| 4/29/2008 | SS | Takeda, Millennium merger clears waiting period hurdle
|
| 4/11/2008 | SS | Takeda begins $25-per-share tender offer for Millennium
|
| 4/10/2008 | SS | Market Commentary: Views on Microsoft-Yahoo! diverge as News Corp., Google, AOL weigh in; Takeda to buy Millennium
|
| 4/10/2008 | SS | Takeda to boost presence in oncology market with acquisition of Millennium Pharmaceuticals
|
| 9/14/2006 | BT | Takeda: Actos cuts risk of heart attack, stroke in diabetic patients
|
| 9/5/2006 | BT | Takeda: Actos reduces risk of recurrent stroke in diabetic patients
|
| 8/16/2006 | BT | Evotec reaches second milestone in Alzheimer's disease collaboration with Takeda Pharmaceutical
|
| 7/31/2006 | BT | Takeda receives FDA approval for duetact to treat type 2 diabetes
|
| 6/19/2006 | BT | Takeda says Rozerem reduces time to fall asleep by five to seven minutes in transient insomnia model
|
| 6/12/2006 | BT | Cephalon, Takeda to promote Provigil in United States
|
| 6/12/2006 | BT | Takeda says Actos reduced cardiovascular events when used against daibetes
|
| 5/22/2006 | BT | Takeda data shows ramelteon may shift sleep-wake cycle in humans
|
| 5/22/2006 | BT | Studies demonstrate Amitiza may help constipation in older people and irritable bowel syndrome
|
| 5/15/2006 | BT | S&P: Takeda Pharmaceutical unchanged
|
| 4/3/2006 | BT | Takeda submits New Drug Application for extended-release formula of diabetes drug ACTOplus met
|
| 4/3/2006 | BT | Takeda: Rozerem study analysis shows insomnia drug cuts time to fall asleep without rebound effects
|
| 3/2/2006 | BT | Lexicon gets $5 million milestone as Takeda chooses LG474 as development target
|
| 2/22/2006 | BT | Takeda wins patent infringement litigation against ANDA filers for generic Actos
|
| 1/20/2006 | BT | Alizyme to receive $2 million milestone from Takeda for cetilistat phase 2 study
|
| 12/6/2005 | BT | Evotec earns first milestone in collaboration with Takeda for Alzheimer's disease target
|
| 6/21/2005 | BT | Moody's gives Takeda Pharmaceutical Aa1
|
